{"id":"W2037994583","doi":"10.1182/blood-2014-08-595801","title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Takeda Pharmaceuticals International; National Cancer Institute; Celgene; Sanofi; Pfizer","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Oncology; Refractory (planetary science); Hodgkin lymphoma; Lymphoma; Phases of clinical research; Chemotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002742244,0.0006852924,0.001005665,0.0001869811,0.0002208604,0.0006277137,0.0003513311,0.0005251752,0.001467612],"category_scores_gemma":[0.001392361,0.0002405816,0.0007622768,0.0002107606,0.000397739,0.0005432855,0.0002870075,0.001383296,0.000247177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004709196,"about_ca_system_score_gemma":0.0005371912,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003994984,"about_ca_topic_score_gemma":0.001478182,"domain_scores_codex":[0.9993079,0.0004207734,0.00003435337,0.00007210232,0.00005339337,0.0001115312],"domain_scores_gemma":[0.9991616,0.0001938198,0.0002286791,0.00007083196,0.00004443157,0.0003005819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.711001,0.03012976,0.02926422,0.0008331668,0.002228966,0.0004928057,0.0005107137,0.002479873,0.04635981,0.0003310029,0.004558897,0.1718098],"study_design_scores_gemma":[0.3760665,0.5518202,0.05951625,0.00006491212,0.0008941422,0.0005445703,0.0001197474,0.001367295,0.004615058,0.0002678789,0.004689972,0.0000333987],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995943,0.002388292,0.000248646,0.0002600875,0.00006233301,0.0003062949,0.0002882763,0.0000170967,0.0004859169],"genre_scores_gemma":[0.9963085,0.001047309,0.0003810894,0.000345136,0.0001104228,0.0003152895,0.0008520206,0.000006813058,0.000633441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002742244,"threshold_uncertainty_score":0.01450258,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01928113197485227,"score_gpt":0.297972365067819,"score_spread":0.2786912330929667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}